Heidelberg – PROGEN Biotechnik GmbH, established manufacturer of
premium research antibodies and AAV gene therapy tools, has signed a non-exclusive
distribution agreement with Thermo Fisher Scientific for selected proprietary antibodies,
including top-selling immunochemicals.

Since 1983, PROGEN has developed a widely cited portfolio of over 1.000 primary and
secondary antibodies for basic and applied life sciences. Sales channels include the company’s
online shop and the collaboration with global distributors. As a leading supplier of research
materials, Thermo Fisher will now offer a choice of 371 primary antibodies globally. Among
them are top-selling products in biomedical research and development, such as lipid
metabolism, cytoskeleton, cell adhesion, or oncology that cover the full range of
immunochemical applications. PROGEN antibodies are available with full service and support
from Thermo Fisher Scientific, also through e-procurement systems.

Joint Managing Directors Katja Betts and Maik Lander welcome the partnership: “We look
forward to tapping the sales power of a leading life science manufacturer to make our
research antibody product widely available in a competitive global market.”

After focusing for more than three decades on research antibody markets, PROGEN is
currently exploring other life science sectors and further expanding its leading role in the
AAV gene therapy market to enable safe and effective treatments.

About PROGEN
Starting out in 1983 as pioneers in antibody manufacturing, PROGEN has since become a globally
operating biotech company that serves the life science and pharma sectors. We believe that our
research antibodies and test kits are more than commodities but enabling tools for the
advancement of research and development in academia and industry alike. Our goal is to deliver
innovative and reliable products that fuel biopharmaceutical and diagnostic progress along the
complete value chain – from the lab to manufacturing and quality control.

PROGEN is continuously expanding its selection of over 1.000 research antibodies in different
formats to enable novel applications that facilitate and accelerate the workflow at the bench.
Building on our core competence in immunochemistry, PROGEN’s portfolio includes adenoassociated virus (AAV) gene therapy tools, phage display technology and libraries for the
generation of novel recombinant antibodies as well as density gradient media for easy cell
fractionation. We place great value on premium quality and are breaking new ground in product
validation to meet the key demand of the research community for high quality, reliable
immunochemicals. Based in Heidelberg, PROGEN has been a 100% subsidiary of R-Biopharm AG
since 2012.